Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tocilizumab

tocilizumab

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tocilizumab

78 trials tracked of tocilizumab: 41 in phase 3 or 4 and 21 with published results. The most-cited published study has 1434 citations.

78Trials tracked
41Phase 3 & 4
0Recruiting
21With published results
Phase distribution
Phase 4 10 Phase 3 31 Phase 2 19 Phase 1 5 Other / NA 13
  1. Phase 3 Efficacy of Tocilizumab on Patients With COVID-19 Completed · 1,434 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia Completed · 1,326 cited
  3. Phase 3 A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) Completed · 645 cited
  4. Phase 4 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors Completed · 230 cited
  5. Phase 3 Treatment of COVID-19 Patients With Anti-interleukin Drugs Completed · 163 cited
  6. Phase 3 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Completed · 131 cited
Show 44 more trials
  1. Phase 4 Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants Completed · 125 cited
  2. Phase 3 To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) Completed · 124 cited
  3. Phase 3 An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed · 37 cited
  4. Phase 3 A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis Completed · 37 cited
  5. Phase 3 A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent Completed · 37 cited
  6. Phase 3 A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed · 37 cited
  7. Phase 3 TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment Completed · 37 cited
  8. Phase 3 A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis Completed · 37 cited
  9. Phase 3 A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. Completed · 37 cited
  10. Phase 3 A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Completed · 37 cited
  11. Phase 3 A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy Completed · 37 cited
  12. Phase 4 Tocilizumab Plus a Short Prednisone Taper for GCA Completed · 33 cited
  13. Phase 3 A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA) Completed · 25 cited
  14. Phase 4 Tocilizumab Real-Life Human Factors (RLHFs) Validation Study Completed · 16 cited
  15. Phase 4 Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab Completed · 7 cited
  16. Phase 4 A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 Completed
  17. Phase 4 Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia Completed
  18. Phase 4 A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) Completed
  19. Phase 4 A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis Completed
  20. Phase 4 A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) Completed
  21. Phase 3 A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis Completed
  22. Phase 3 A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs Completed
  23. Phase 3 A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA). Completed
  24. Phase 3 A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis Completed
  25. Phase 3 A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA) Completed
  26. Phase 3 A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia Completed
  27. Phase 3 An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis Completed
  28. Phase 3 A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis Completed
  29. Phase 3 A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis. Completed
  30. Phase 3 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed
  31. Phase 3 A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis Completed
  32. Phase 3 A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis Completed
  33. Phase 3 A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis Completed
  34. Phase 3 A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis Completed
  35. Phase 3 An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies Completed
  36. Phase 2 Treg Modulation With CD28 and IL-6 Receptor Antagonists Completed
  37. Phase 2 A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation Completed
  38. Phase 2 A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Completed
  39. Phase 2 AIDS 347: IL-6 Blockade in Treated HIV Infection Completed
  40. Phase 2 Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation Completed
  41. Phase 2 Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed
  42. Phase 2 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant Completed
  43. Phase 2 A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis Completed
  44. Phase 2 A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment Completed

Showing the 50 most-cited and recently-updated of 78 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome
Pediatrics Sys. Review
Review of ruxolitinib for systemic juvenile arthritis with macrophage activation syndrome Two children with severe arthritis found relief using a new drug approach
This narrative review synthesizes a retrospective case series and literature search on ruxolitinib for systemic juvenile idiopathic arthriti…
Two children with severe arthritis complications found relief using a new drug approach, offering hope for those who struggle with standard …
Frontiers May 28, 2026
Intravenous tocilizumab improves clinical activity in moderate-to-severe thyroid eye disease patients
Diabetes & Endocrinology Cohort
Intravenous tocilizumab improves clinical activity in moderate-to-severe thyroid eye disease patients Doctors spot four signs that predict which eye disease patients will heal fastest
This retrospective cohort study evaluated intravenous tocilizumab in 234 patients with moderate-to-severe thyroid eye disease at Beijing Ton…
A new study reveals four simple blood tests that tell doctors if a specific eye drug will work for you soon.
Frontiers Apr 27, 2026
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
Oncology
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
medRxiv Apr 27, 2026
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
Oncology Cohort
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel.
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Frontiers Apr 24, 2026
Retrospective review of tocilizumab, rituximab, and azathioprine in chronic relapsing inflammatory optic neuropathy
Neurology
Retrospective review of tocilizumab, rituximab, and azathioprine in chronic relapsing inflammatory optic neuropathy New Clue Found in Stubborn Eye Inflammation
This retrospective analysis reviews tocilizumab, rituximab, and azathioprine use in 60 patients with chronic relapsing inflammatory optic ne…
Knowing a patient's blood marker status can guide doctors to the right therapy to stop recurring eye inflammation.
medRxiv Apr 23, 2026
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes
Pulmonology & Critical Care Cohort
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes What helps hospitalized COVID-19 patients survive? A new model offers clues
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments.
When COVID-19 hits hard, doctors need better tools to predict who might get worse.
medRxiv Apr 16, 2026
Biological DMARDs show marginal patient-reported outcome benefits over conventional therapy in early rheumatoid arthritis
Rheumatology RCT
Biological DMARDs show marginal patient-reported outcome benefits over conventional therapy in early rheumatoid arthritis Early rheumatoid arthritis patients report similar symptom relief with different treatment approaches
This open-label randomized trial in 795 newly diagnosed, DMARD-naïve RA patients compared three biological DMARDs plus methotrexate against …
In early rheumatoid arthritis, patients reported similar pain relief and quality-of-life improvements whether they started with conventional…
Apr 9, 2026